BRCA2 and melanoma: In particular for the case of CanDrA meta-predictor, as all but one TP53 SNVs were predicted to be ‘drivers’ by all CanDrA algorithms (that is, CanDrA breast/lung/melanoma), whereas all BRCA1 and BRCA2 mutations were predicted to be ‘drivers’ by CanDrA (breast) but almost exclusively ‘passengers/no-call’ by CanDrA (lung/melanoma).